Social Ontology and the Identification of Generic Performativity in Social Science: A Case of Performative Financialization
Philosophy of the Social Sciences · 2023-07 · 53 (4) · 303-326
DOI: 10.1177/00483931231177478 ↗Kurz gefasst
Fachartikel in der Zeitschrift Philosophy of the Social Sciences, online erschienen am 25.05.2023. Verfasst von Noriaki Okamoto. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Although social ontology (SO) has attracted the attention of scholars in various disciplines, how it is applied to social scientific studies is still under-researched. To tackle this issue, this paper initially considers major streams of research on SO. It then argues that one of the aims of SO in the social sciences is to identify the rhetorical expression of social dynamism. To support this argument, the present study introduces a perspective of performativity and proposes that generic performativity should be identified by social scientists. Finally, such an attempt is demonstrated with reference to the global pursuit of financialization.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Okamoto, N. (2023). Social Ontology and the Identification of Generic Performativity in Social Science: A Case of Performative Financialization. Philosophy of the Social Sciences, 53(4), 303-326. https://doi.org/10.1177/00483931231177478
Vancouver
Okamoto N. Social Ontology and the Identification of Generic Performativity in Social Science: A Case of Performative Financialization. Philosophy of the Social Sciences. 2023;53(4):303-326. doi:10.1177/00483931231177478
BibTeX
@article{Okamoto2023,
author = {Okamoto, Noriaki},
title = {Social Ontology and the Identification of Generic Performativity in Social Science: A Case of Performative Financialization},
journal = {Philosophy of the Social Sciences},
year = {2023},
volume = {53},
number = {4},
pages = {303--326},
doi = {10.1177/00483931231177478}
}
EUVIMED